Key Takeaways
- FDA's Expedited IND Pilot, opened September 15, will select 8 to 10 sponsor and research-institution pairs, with applications due October 30, 2026, to shorten first-in-human trials that can take up to 2 years in the U.S.
- The pilot lets FDA review IND components on a rolling basis and encourages IRB review and site activation to run in parallel, but FDA keeps full authority, including clinical hold.
- Annual turnover among patient-facing clinical research professionals runs 35% to 61%, and average tenure is just 1.5 to 2 years, against 4.1 years for the typical U.S. employee, according to the Society for Clinical Research Sites.
- Sites estimate that recruiting and training one patient-facing replacement costs about six months of that person's salary, a hidden tax on every accelerated start-up.
Getting a new medicine into its first human volunteer takes up to two years in the United States, a delay that has pushed early-phase work toward other countries. On September 15, FDA launched an Expedited IND Pilot to claw some of that time back. The design is sensible and the ambition is real. But the pilot speeds up the paperwork before a first patient is dosed, and the people who must carry a program from approval to enrollment are the same overstretched site teams that already turn over faster than almost any workforce in health care.
What the Pilot Changes
Under the pilot, drug sponsors apply as paired teams with a qualified research institution, or QRI. According to FDA's program page, a QRI supplies expert recommendations on the pharmacology, toxicology, clinical and manufacturing sections of a first-in-human IND, and FDA prioritizes institutions with U.S. operations, multidisciplinary support and clinical infrastructure that is either owned or backed by a formal, documented partnership. Board-certified physicians with direct Phase 1 design experience are a stated requirement.
Reporting from Applied Clinical Trials adds the mechanics. FDA expects to select 8 to 10 sponsor and QRI pairs for the first cohort, will accept individual IND components on a rolling basis as they are completed, and wants to see IRB review and clinical trial site activation coordinated alongside IND development rather than after it. The standard review window is 30 days, and the agency retains full regulatory authority, including the power to place a clinical hold. Applications close at 11:59 p.m. ET on October 30, 2026. The pilot sits within HHS's Operation TrialBlazer, the department's clinical trials reform effort.
The notable phrase is site activation. Earlier reforms mostly targeted what sponsors submit. This one explicitly reaches into the operational steps that follow, which is where a healthcare network or academic medical center either has the people to move quickly or does not.
The Workforce Underneath the Timeline
Speed at the front end assumes stable teams at the back end, and the data on that assumption is not encouraging. The Society for Clinical Research Sites reports in its staffing and retention analysis that annual turnover among patient-facing clinical research professionals has risen to between 35% and 61%. Those professionals stay in their roles an average of 1.5 to 2 years, compared with 4.1 years for the average American employee. Sites put the added cost of recruiting and training one new patient-facing team member at roughly six months of that person's salary.
The strain shows up in surveys too. A summary in HCI Innovation Group cites a 2022 OpenClinica survey in which 61% of clinical research staff reported being completely or somewhat burned out, and 52% of site respondents said turnover had increased since 2020. Those figures are a few years old, so they are best read as a direction of travel rather than a current reading. Even so, they describe the environment into which a faster start-up process will land.
The mismatch is easy to picture. A pilot that compresses IND preparation and runs IRB review in parallel produces a site that is ready to activate sooner. If the coordinators, nurses and Phase 1 clinicians it needs are mid-turnover, that readiness is theoretical, and the weeks saved in Washington are spent re-hiring in the clinic.
Proportionality Has to Reach the Site
One industry voice quoted by Applied Clinical Trials, Dr. Richard Graham of TruTechnologies, argued that "proportionality has to extend into trial conduct more broadly" beyond the start-up phase. It is a useful frame. If the goal is a first-in-human trial that begins faster, the same logic applies to how much documentation, coordination and credentialing each site staff member absorbs once the trial is running.
That is where three familiar operating problems meet the pilot. Clinicians must be credentialed and placed quickly, as AMN Healthcare examines in Faster Access, Fewer Steps. Teams under sustained pressure need support to stay, a theme in Lyra Health's Thriving Under Pressure. And multidisciplinary care teams must actually coordinate, the premise of One Medical's The Benefits of Collaborative Care. None of these is a trial design tool, but each addresses a constraint that trial design cannot fix.
- Ask applicants about staffing, not just science. When choosing a QRI partner, request turnover and vacancy data for the Phase 1 unit alongside the regulatory credentials, since a documented partnership is only as reliable as the people behind it.
- Budget for backfill. At about six months of salary per replacement, retention belongs in the program budget as a schedule risk, not an HR line item.
- Plan credentialing early. Rolling IND review and parallel IRB work compress the calendar, so clinician credentialing and placement should start when the application does, not after acceptance.
- Protect the coordinators. Cut duplicate documentation and data entry where the protocol allows, because burnout and turnover feed each other and the pilot cannot fix either.
- Track time to first patient, not just time to IND. Measure the full interval from IND preparation to enrollment, the interval FDA says it wants to reduce, so gains at the front end are not lost at the site.
FDA is right to treat first-in-human delay as a competitiveness problem, and the pilot is a credible experiment. The open question is whether the sites that must execute it can hold their teams together long enough to benefit. Sponsors that ask that question before they apply will be the ones whose faster paperwork becomes a faster first patient.
